The DOI matches its Crossref record; 12 of the 14 references it cites were found in a registry or an index.
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
Open accessAbstract
Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5-4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5-2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SARS-CoV-2 seroprevalence in our study is comparable with estimates from large population-based serosurveys in China, Switzerland, Spain, and the United States after the initial epidemic peak and after many tens of thousands of deaths (9, 10, 17, 18).”
From Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors (2021) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Self-citationSARS-CoV-2 Infection in Children
Lü, X., Zhang, L., Du, H. N., Zhang, J., Li, Y. Y., Qu, J., Zhang, W., Wang, Y., Bao, S., Li, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2005073 · Cited by 2,423
The Empirical Distribution Function with Arbitrarily Grouped, Censored and Truncated Data
Turnbull, B. W. (1976) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/j.2517-6161.1976.tb01597.x · Cited by 1,835
Hu, Z., Song, C., Xu, C., Jin, G., Chen, Y., Xu, X., Ma, H., Chen, W., Lin, Y., Zheng, Y., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1661-4 · Cited by 1,429
Self-citationA Novel Coronavirus Emerging in China — Key Questions for Impact Assessment
Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D. A. J., & de Wit, E. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2000929 · Cited by 1,418
Cited by
Sorted by citations
Gómez‐Ochoa, S. A., Franco, O. H., Rojas, L. Z., Raguindin, P. F., Roa‐Díaz, Z. M., Minder, B., Guevara, S. L. R., Echeverría, L. E., Glišić, M., & Muka, T. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa191 · Cited by 788
FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation
Junqueira, C., Crespo, Â. C., Ranjbar, S., de Lacerda, L., Lewandrowski, M., Ingber, J., Parry, B. A., Ravid, S., Clark, S. A., Schrimpf, M. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04702-4 · Cited by 699
Infection fatality rate of COVID-19 inferred from seroprevalence data
Ioannidis, J. P. A. (2021) · Bulletin of the World Health Organization · doi:10.2471/blt.20.265892 · Cited by 684
Reconstruction of the full transmission dynamics of COVID-19 in Wuhan
Hao, X., Cheng, S., Wu, D., Wu, T., Lin, X., & Wang, C. (2020) · Nature · doi:10.1038/s41586-020-2554-8 · Cited by 423
The emergence, genomic diversity and global spread of SARS-CoV-2
Li, J., Lai, S., Gao, G. F., & Shi, W. (2021) · Nature · doi:10.1038/s41586-021-04188-6 · Cited by 427
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis
Rostami, A., Sepidarkish, M., Leeflang, M., Riahi, S. M., Shiadeh, M. N., Esfandyari, S., Mokdad, A. H., Hotez, P. J., & Gasser, R. B. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.020 · Cited by 362
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic
To, K. K., Sridhar, S., Chiu, K. H., Hung, D. L. L., Li, X., Hung, I. F., Tam, A. R., Chung, T. W., Chan, J. F., Zhang, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1898291 · Cited by 359
COVID-19 in early 2021: current status and looking forward
Wang, C., Wang, Z., Wang, G., Lau, J. Y., Zhang, K., & Li, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00527-1 · Cited by 358
Self-citationGalanis, P., Vraka, I. S., Fragkou, D., Bilali, A., & Καϊτελίδου, Δ. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.11.008 · Cited by 323
Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
Uyoga, S., Adetifa, I. M. O., Karanja, H. K., Nyagwange, J., Tuju, J., Wanjiku, P., Aman, R., Mwangangi, M., Amoth, P., Kasera, K., et al. (2021) · Science · doi:10.1126/science.abe1916 · Cited by 328
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
Rodríguez, Y., Novelli, L., Rojas, M., Santis, M. D., Acosta‐Ampudia, Y., Monsalve, D. M., Ramírez-Santana, C., Costanzo, A., Ridgway, W. M., Ansari, A. A., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102506 · Cited by 319
SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden
Rudberg, A., Havervall, S., Månberg, A., Falk, A. J., Aguilera, K., Ng, H., Gabrielsson, L., Salomonsson, A., Hanke, L., Murrell, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18848-0 · Cited by 296
Liu, H., Dai, E., Xiao, R., Zhou, Z., Zhang, M., Bai, Z., Shao, Y., Qi, K., Tu, J., Wang, C., et al. (2020) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2020.129196 · Cited by 272
Self-citationAnand, S., Montez‐Rath, M. E., Han, J., Bozeman, J., KERSCHMANN, R. L., Beyer, P., Parsonnet, J., & Chertow, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32009-2 · Cited by 265
Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York
Rosenberg, E. S., Tesoriero, J. M., Rosenthal, E. M., Chung, R., Barranco, M. A., Styer, L. M., Parker, M. M., Leung, S.-Y. J., Morne, J. E., Greene, D., et al. (2020) · Annals of Epidemiology · doi:10.1016/j.annepidem.2020.06.004 · Cited by 264
Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
Li, K., Huang, B., Wu, M., Zhong, A., Li, L., Cai, Y., Wang, Z., Wu, L., Zhu, M., Li, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19943-y · Cited by 257
COVID-19 Antibody Tests and Their Limitations
Liu, G., & Rusling, J. F. (2021) · ACS Sensors · doi:10.1021/acssensors.0c02621 · Cited by 226
He, Z., Ren, L., Yang, J., Guo, L., Feng, S., Ma, C., Wang, X., Leng, Z., Tong, X., Zhou, W., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00238-5 · Cited by 226
Self-citationPopulation-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review
Lai, C.-C., Wang, J.-H., & Hsueh, P. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.10.011 · Cited by 193
Wang, C., Yang, X., Gu, B., Liu, H., Zhou, Z., Shi, L., Cheng, X., & Wang, S. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03484 · Cited by 196
Escandón-Vargas, K., Rasmussen, A. L., Bogoch, I. I., Murray, E. J., Escandón, K., Popescu, S. V., & Kindrachuk, J. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06357-4 · Cited by 206
Meyerowitz, E. A., Richterman, A. G., Bogoch, I. I., Low, N. N., & Çevik, M. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30837-9 · Cited by 158
Hartman, A. L., Nambulli, S., McMillen, C. M., White, A. G., Tilston‐Lunel, N. L., Albe, J. R., Cottle, E. L., Dunn, M., Frye, L. J., Gilliland, T. H., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008903 · Cited by 140
Wang, C., Cheng, X., Liu, L., Zhang, X., Yang, X., Zheng, S., Rong, Z., & Wang, S. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c11461 · Cited by 141
Antibody Responses in COVID-19: A Review
Chvatal‐Medina, M., Cortina, Y. A. M., Grajales, P. J. P., Velilla, P. A., & Rugeles, M. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633184 · Cited by 142
Martín, J. E.-S., Klapsa, D., Wilton, T., Zambon, M. C. F. A., Bentley, E. M., Bujáki, E., Fritzsche, M., Mate, R., & Majumdar, M. (2020) · Viruses · doi:10.3390/v12101144 · Cited by 137
Carrat, F., de Lamballerie, X. N., Rahib, D., Blanché, H., Lapidus, N., Artaud, F., Kab, S., Renuy, A., de Edelenyi, F. S., Meyer, L., et al. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyab110 · Cited by 147
Antibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections
Lei, Q., Li, Y., Hou, H., Wang, F., Ouyang, Z., Zhang, Y., Lai, D., Ndzouboukou, J. B., Xu, Z., Zhang, B., et al. (2020) · Allergy · doi:10.1111/all.14622 · Cited by 124
McAndrews, K. M., Dowlatshahi, D. P., Dai, J., Becker, L. M., Hensel, J., Snowden, L. M., Leveille, J. M., Brunner, M. R., Holden, K. W., Hopkins, N. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142386 · Cited by 122
Zhang, J., Lee, A. C.-Y., Chu, H., Chan, J. F., Fan, Z., Li, C., Liu, F., Chen, Y., Yuan, S., Poon, V. K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa995 · Cited by 128
SARS-CoV-2 seroprevalence in COVID-19 hotspots
Eckerle, I., & Meyer, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31482-3 · Cited by 119
Perkmann, T., Perkmann‐Nagele, N., Breyer, M., Breyer‐Kohansal, R., Burghuber, O. C., Hartl, S., Aletaha, D., Sieghart, D., Quehenberger, P., Marculescu, R., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa198 · Cited by 115
Han, H., Wang, C., Yang, X., Zheng, S., Cheng, X., Liu, Z., Zhao, B., & Xiao, R. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.130897 · Cited by 116
Antibody Response After SARS-CoV-2 Infection and Implications for Immunity
Arkhipova-Jenkins, I., Helfand, M., Armstrong, C., Gean, E. G., Anderson, J., Paynter, R. A., & Mackey, K. (2021) · Annals of Internal Medicine · doi:10.7326/m20-7547 · Cited by 116
Wu, Z., Harrich, D., Li, Z., Hu, D., & Li, D. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2171 · Cited by 114
Self-citationHippich, M., Holthaus, L., Assfalg, R., Zapardiel‐Gonzalo, J., Kapfelsperger, H., Heigermoser, M., Haupt, F., Ewald, D., Welzhofer, T., Marcus, B. A., et al. (2020) · Med · doi:10.1016/j.medj.2020.10.003 · Cited by 111
Liu, T., Hsiung, J., Zhao, S., Kost, J., Sreedhar, D., Hanson, C. V., Olson, K., Keare, D., Chang, S. T., Bliden, K. P., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00642-4 · Cited by 105
Aziz, N. A., Corman, V. M., Echterhoff, A. K. C., Müller, M. A., Richter, A. M., Schmandke, A., Schmidt, M. L., Schmidt, T. H., de Vries, F. M., Drosten, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22351-5 · Cited by 107
SARS-CoV-2 Transmission among Marine Recruits during Quarantine
Letizia, A. G., Ramos, I., Obla, A., Goforth, C. W., Weir, D. L., Ge, Y., Bamman, M. M., Dutta, J., Ellis, E., Estrella, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2029717 · Cited by 106
Maria, E. D., Latini, A., Borgiani, P., & Novelli, G. (2020) · Human Genomics · doi:10.1186/s40246-020-00280-6 · Cited by 93
Clinical and Laboratory Diagnosis of SARS-CoV-2, the Virus Causing COVID-19
da Silva, S. J. R., da Silva, C. T. A., Guarines, K. M., Mendes, R. P. G., Pardee, K., Kohl, A., & Pena, L. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00274 · Cited by 95
Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
Slot, E., Hogema, B. M., Reusken, C. B. E. M., Reimerink, J. H. J., Molier, M., Karregat, J. H. M., IJlst, J., Novotny, V. M. J., van Lier, R. A. W., & Zaaijer, H. L. (2020) · Nature Communications · doi:10.1038/s41467-020-19481-7 · Cited by 88
Álvarez-Antonio, C., Meza‐Sánchez, G., Calampa, C., Casanova, W., Carey, C., Alava, F., Rodríguez, H., & Quispe, A. M. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00173-x · Cited by 88
Prevalence and determinants of SARS-CoV-2 vaccine hesitancy in Hong Kong: A population-based survey
Luk, T. T., Zhao, S. Z., Wu, Y. S., Wong, J. Y. H., Wang, M. P., & Lam, T. H. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.036 · Cited by 87
Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa: A systematic review and meta‐analysis
Chisale, M., Ramazanu, S., Mwale, S. E., Kumwenda, P., Chipeta, M. C., Kaminga, A. C., Nkhata, O., Nyambalo, B. W., Chavura, E., & Mbakaya, B. C. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2271 · Cited by 81
Hu, F., Chen, F., Ou, Z., Fan, Q., Tan, X., Wang, Y., Pan, Y., Ke, B., Li, L., Guan, Y., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00550-2 · Cited by 87
Four months into the COVID-19 pandemic, Sweden’s prized herd immunity is nowhere in sight
Orlowski, E. J. W., & Goldsmith, D. J. A. (2020) · Journal of the Royal Society of Medicine · doi:10.1177/0141076820945282 · Cited by 89
Hossain, A., Nasrullah, S. M., Tasnim, Z., Hasan, M. K., & Hasan, M. M. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100770 · Cited by 74
Patel, U. K., Malik, P., Mehta, D., Shah, D., Kelkar, R., Pinto, C., Suprun, M., Dhamoon, M. S., Hennig, N., & Sacks, H. S. (2020) · Journal of Global Health · doi:10.7189/jogh.10.020506 · Cited by 70
Junqueira, C., Crespo, Â., Ranjbar, S., Ingber, J., Parry, B., Ravid, S., Lacerda, L. B. D., Lewandrowski, M., Clark, S., Ho, F., et al. (2021) · doi:10.1101/2021.03.06.21252796 · Cited by 70
Ojeda, D. S., Ledesma, M. M. G. L., Pallarés, H. M., Navarro, G. S. C., Sánchez, L., Perazzi, B. E., Villordo, S. M., Alvarez, D. E., BioBanco Working Group, Echavarría, M., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009161 · Cited by 67
Sims, M. D., Maine, G. N., Childers, K. L., Podolsky, R. H., Voss, D. R., Berkiw-Scenna, N., Oh, J., Heinrich, K., Keil, H., Kennedy, R. H., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1684 · Cited by 67
Swank, Z., Michielin, G., Yip, H. M., Cohen, P., Andrey, D. O., Vuilleumier, N., Kaiser, L., Eckerle, I., Meyer, B., & Maerkl, S. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025289118 · Cited by 65
Wang, H., Ai, J., Loeffelholz, M. J., Tang, Y., & Zhang, W. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1826362 · Cited by 62
Kayı, İ., Madran, B., Keske, Ş., Karanfil, Ö., Arribas, J. R., Psheniсhnaya, N., Petrosillo, N., Gönen, M., & Ergönül, Ö. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.036 · Cited by 61
Akinbami, L. J., Vuong, N., Petersen, L. R., Sami, S., Patel, A. K., Lukacs, S. L., Mackey, L., Grohskopf, L. A., Shehu, A., & Atas, J. G. (2020) · Emerging infectious diseases · doi:10.3201/eid2612.203764 · Cited by 61
Maximizing and evaluating the impact of test-trace-isolate programs: A modeling study
Grantz, K. H., Lee, E. C., McGowan, L. D., Lee, K. H., Metcalf, C. J. E., Gurley, E. S., & Lessler, J. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003585 · Cited by 61
Immune reactivity during COVID-19: Implications for treatment
Claudio Napoli, A., Benincasa, G., Criscuolo, C., Faenza, M., Liberato, C., & Rusciano, M. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.01.001 · Cited by 60
Ruggiero, A., Piubelli, C., Calciano, L., Accordini, S., Valenti, M. T., Carbonare, L. D., Siracusano, G., Lopalco, L., Temperton, N. J., Tiberti, N., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103888 · Cited by 62
High seroprevalence but short‐lived immune response to SARS‐CoV‐2 infection in Paris
Anna, F., Goyard, S., Lalanne, A. I., Névo, F., Gransagne, M., Souque, P., Louis, D., Gillon, V., Turbiez, I., Bidard, F., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202049058 · Cited by 58
Stefanelli, P., Bella, A., Fedele, G., Pancheri, S., Leone, P., Vacca, P., Neri, A., Carannante, A., Fazio, C., Benedetti, E., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.11.013 · Cited by 56
Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain
Varona, J. F., Madurga, R., Peñalver, F. J., Abarca, E., Almirall, C., Cruz, M., Ramos, E., & Castellano, J. M. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa277 · Cited by 56
Li, Y., Lai, D., Lei, Q., Xu, Z., Wang, F., Hou, H., Chen, L., Wu, J., Ren, Y., Ma, M., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00612-5 · Cited by 53
Lee, A. S., Kim, S. M., Kim, K. R., Park, C., Lee, D., Heo, H. R., Chi, H. J., & Kim, C. S. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.133245 · Cited by 57
Wang, C., Shi, D., Wan, N., Yang, X., Liu, H., Gao, H., Zhang, M., Bai, Z., Li, D., Dai, E., et al. (2021) · The Analyst · doi:10.1039/d1an00304f · Cited by 53
Self-citationCOVID-19 and lombardy: TESTing the impact of the first wave of the pandemic
Perico, L., Tomasoni, S., Peracchi, T., Perna, A., Pezzotta, A., Remuzzi, G., & Benigni, A. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103069 · Cited by 53
Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study
Majiya, H., Aliyu‐Paiko, M., Balogu, T. V., Musa, D. A., Salihu, I. M., Kawu, A. A., Bashir, I. Y., Sani, A. R., John, B., Muhammad, A. T., et al. (2023) · JMIRx Med · doi:10.2196/29587 · Cited by 56
Vertical Flow Cellulose-Based Assays for SARS-CoV-2 Antibody Detection in Human Serum
Kim, S., Hao, Y., Miller, E. A., Tay, D. M. Y., Yee, E. H., Kongsuphol, P., Jia, H., McBee, M. E., Preiser, P. R., & Sikes, H. D. (2021) · ACS Sensors · doi:10.1021/acssensors.1c00235 · Cited by 53
Yang, P., Qi, J., Zhang, S., Wang, X., Bi, G., Yang, Y., Sheng, B., & Yang, G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236857 · Cited by 51
Kim, D. S., Rowland‐Jones, S., & Gea‐Mallorquí, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571481 · Cited by 51
Screening and testing for COVID ‐19 before surgery
Kovoor, J. G., Tivey, D. R., Williamson, P., Tan, L., Kopunic, H. S., Babidge, W., Collinson, T. G., Hewett, P. J., Hugh, T. J., Padbury, R. T. A., et al. (2020) · ANZ Journal of Surgery · doi:10.1111/ans.16260 · Cited by 49
SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
Vogl, T. J., Leviatan, S., & Segal, E. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100191 · Cited by 44
SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020
Díaz-Vélez, C., Failoc‐Rojas, V. E., Valladares-Garrido, M. J., Colchado, J., Carrera-Acosta, L., Becerra, M., Paico, D. M., & Ocampo-Salazar, E. (2021) · PeerJ · doi:10.7717/peerj.11210 · Cited by 43
Dimcheff, D. E., Schildhouse, R. J., Hausman, M. S., Vincent, B. M., Markovitz, E., Chensue, S. W., Deng, J. C., McLeod, M., Hagan, D., Russell, J., et al. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.1220 · Cited by 42
Fuereder, T., Berghoff, A. S., Heller, G., Haslacher, H., Perkmann, T., Straßl, R. P., Berger, J. M., Puhr, H. C., Kreminger, J. E., Moik, F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000889 · Cited by 39
Saadoun, D., Vieira, M., Vautier, M., Baraliakos, X., Andreica, I., da Silva, J. A. P., Sousa, M., Luís, M., Khmelinskii, N., Gracia, J. M. A., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00112-0 · Cited by 40
Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Lu, L., Zhang, H., Zhan, M., Jiang, J., Yin, H., Dauphars, D. J., Li, S.-Y., Li, Y., & He, Y.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1859-y · Cited by 41
Richard, A., Wisniak, A., Perez‐Saez, J., Garrison‐Desany, H. M., Petrović, D., Piumatti, G., Baysson, H., Picazio, A., Pennacchio, F., Ridder, D. D., et al. (2021) · Scandinavian Journal of Public Health · doi:10.1177/14034948211048050 · Cited by 40
Herrington, D. M., Sanders, J. W., Wierzba, T. F., Alexander‐Miller, M. A., Espeland, M. A., Bertoni, A. G., Mathews, A., Seals, A. L., Munawar, I., Runyon, M. S., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06517-6 · Cited by 36
Assessing the extent of SARS-CoV-2 circulation through serological studies
Koopmans, M., & Haagmans, B. L. (2020) · Nature Medicine · doi:10.1038/s41591-020-1018-x · Cited by 36
Skowronski, D. M., Sekirov, I., Sabaiduc, S., Zou, M., Morshed, M. G., Lawrence, D., Smolina, K., Ahmed, M. A., Galanis, E., Fraser, M., et al. (2020) · medRxiv · doi:10.1101/2020.07.13.20153148 · Cited by 34
Distinct lipid metabolic dysregulation in asymptomatic COVID-19
Hao, Y., Zhang, Z., Feng, G., Chen, M., Wan, Q., Lin, J., Wu, L., Nie, W., & Chen, S. (2021) · iScience · doi:10.1016/j.isci.2021.102974 · Cited by 36
Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea
Noh, J. Y., Seo, Y. B., Yoon, J. G., Seong, H., Hyun, H., Lee, J., Lee, N., Jung, S., Park, M.-J., Song, W., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e311 · Cited by 35
da Cunha, L. E. R., Stolet, A. A., Strauch, M. A., Pereira, V. A. R., Dumard, C. H., Gomes, A. M. O., Monteiro, F. L. L., Higa, L. M., Souza, P. N. C., Fonseca, J. G. D. S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103315 · Cited by 37
Zhang, Y., Ma, X., Yan, G., Wu, Y., Chen, Y., Zhou, Z., Wan, N., Su, W., Liu, F., Dai, M., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101680 · Cited by 34
Haarhaus, M. L., Santos-Araújo, C., Haase, M., Veiga, P. M., Lucas, C., & Macario, F. J. G. R. M. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab037 · Cited by 33
Transmission dynamics and control measures of COVID-19 outbreak in China: a modelling study
Zhang, X., Vynnycky, E., Charlett, A., Angelis, D. D., Chen, Z., PHE COVID-19 modelling group, & Liu, W. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-81985-z · Cited by 36
Popova, A. Y., Andreeva, E. E., Babura, E. A., Балахонов, С. В., Bashketova, N. S., Bulanov, M. V., Valeullina, N. N., Goryaev, D. V., Николаевна, Д. Т., Ezhlova, E. B., et al. (2021) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-fod-1684 · Cited by 31
Muñoz‐Medina, J. E., Grajales-Muñíz, C., Salas-Lais, Á. G., Fernandes-Matano, L., López-Macías, C. I. R., Monroy-Muñoz, I. E., Coy-Arechavaleta, A. S., Palomec-Nava, I. D., Duque-Molina, C., Madera-Sandoval, R. L., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9040850 · Cited by 30
SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic
Popova, A. Y., Смирнов, В. С., Andreeva, E. E., Babura, E. A., Балахонов, С. В., Bashketova, N. S., Александровна, Б. С., Bulanov, M. V., Valeullina, N. N., Ветров, В. В., et al. (2021) · Viruses · doi:10.3390/v13081648 · Cited by 30
Radev, S. T., Graw, F., Chen, S., Mutters, N. T., Eichel, V. M., Bärnighausen, T., & Köthe, U. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009472 · Cited by 42
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Acebes, E. O., Navarro, M. J. G., & Khosravi‐Shahi, P. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102102 · Cited by 30
Pan, Y., Li, X., Yang, G., Fan, J., Tang, Y., Hong, X., Guo, S., Li, J., Yao, D., Cheng, Z., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.09.044 · Cited by 31
Loubière, S., Monfardini, E., Allaria, C., Mosnier, M., Allibert, A., Ninove, L., Bosetti, T., Farnarier, C., Hamouda, I., Auquier, P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255498 · Cited by 31
Kataria, Y., Cole, M., Duffy, E. R., Cena, K. O. C. D. L., Schechter‐Perkins, E. M., Bouton, T. C., Werler, M. M., Pierre, C. M., Ragan, E. J., Weber, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89107-5 · Cited by 30
Precision shielding for COVID-19: metrics of assessment and feasibility of deployment
Ioannidis, J. P. A. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2020-004614 · Cited by 31
Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19
Ni, Y., Alu, A., Hong, L., Wang, Y., Wu, M., & Wei, X. (2021) · Molecular Biomedicine · doi:10.1186/s43556-020-00015-y · Cited by 32
Discovery Proteomics for COVID-19: Where We Are Now
McArdle, A., Washington, K. E., Chazarin, B., Binek, A., Manalo, D.-M., Rivas, A., Ayres, M., Pandey, R., Phebus, C., Raedschelders, K., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00475 · Cited by 28
Modeling the Novel Coronavirus (SARS-CoV-2) Outbreak in Sicily, Italy
Maugeri, A., Barchitta, M., Battiato, S., & Agodi, A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17144964 · Cited by 28
Lombardi, A., Mangioni, D., Consonni, D., Cariani, L., Bono, P., Cantù, A. P., Tiso, B., Carugno, M., Muscatello, A., Lunghi, G., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047216 · Cited by 29
Metadata
- Authors
- Xu, X., Sun, J., Nie, S., Li, H., Kong, Y., Liang, M., Hou, J., Huang, X., Li, D., Ma, T., Peng, J., Gao, S., Shao, Y., Zhu, H., Lau, J. Y.-N., Wang, G., Xie, C., Jiang, L., Huang, A., Yang, Z., Zhang, K., & Hou, F. F.
- Affiliations
- Nanfang Hospital (CN)
- Kingmed Diagnostics (CN)
- First People's Hospital of Foshan (CN)
- Honghu People’s Hospital (CN)
- First People's Hospital of Jingzhou (CN)
- Jingzhou Central Hospital (CN)
- Honghu Hospital of Traditional Chinese Medicine (CN)
- Hong Kong Polytechnic University (HK)
- Tsinghua University (CN)
- University of Electronic Science and Technology of China (CN)
- Chongqing Medical University (CN)
- Macau University of Science and Technology (MO)
- Corresponding author
- Huang, Ailong
- Yang, Zhenglin
- Zhang, Kang
- Hou, Fan Fan
- ORCID
- Venue
- Nature Medicine
- Published
- 2020-06-05
- Volume
- 26
- Issue
- 8
- Pages
- 1193-1195
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3033219406
- Cited by
- 405
- References
- 14
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 16 · 2023: 28 · 2022: 58 · 2021: 174 · 2020: 118
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-08-18)
- Open access
- bronze
- doi.org
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundo para o Desenvolvimento das Ciências e da Tecnologia (0035/2020/A)
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2020GZR110306001, 2018GZR110102004, 2018GZR0201003)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, seroprevalence, immunoglobulin M, IgG, serological surveillance, asymptomatic infection, Wuhan, hemodialysis patients, healthcare workers, regional variation
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Antibodies, Viral, China, Female, Health Personnel, Humans, Immunoglobulin G, Immunoglobulin M, Male, Middle Aged, Pneumonia, Viral, Seroepidemiologic Studies, Coronavirus Infections, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
